Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
Drugs for Neglected Diseases Initiative in 32 African countries, in India, Ecuador and in Colombia, and included in the WHO Model List of Essential Medicines. More than 437 million treatments had been distributed. A technology transfer agreement has been signed with industrial partner Zenufa in Tanzania in order to provide an additional source of ASAQ. ASAQ was handed over to the MMV Access and Product Management Team in May 2015. The second antimalarial treatment developed by DND"i" is a fixed-dose combination of artesunate and mefloquine launched in 2008. It was developed by an international collaboration within the FACT Project Consortium. It has a simple and